fig1

Figure 1. Prevalence of actionable genomic alterations in intrahepatic cholangiocarcinoma. IDH1/2^Mut: isocitrate dehydrogenase-1/2 mutation; BAP1^Mut: BRCA1-Associated Protein 1 mutation; FGFR2^Fus: fibroblast growth factor receptor 2 fusion; HER2^Amp: human epidermal growth factor 2 amplification; BRAF^V600E: BRAF V600E mutation; NTRK^Fus: NTRK fusion; RET^Fus: RET fusion; MSI^high: high microsatellite instability; TMB^high: high tumor mutation burden.